The role of sibutramine in weight management—towards a blueprint for a sibutramine weight management system

被引:0
|
作者
WPT James
N Finer
机构
[1] Director,
[2] Public Health Policy Group,undefined
[3] Chairman,undefined
[4] International Obesity Task Force,undefined
[5] The Luton and Dunstable Hospital NHS Trust,undefined
来源
关键词
blueprint; obesity/weight management; assessment; monitoring; treatment goals;
D O I
暂无
中图分类号
学科分类号
摘要
Sibutramine offers a new opportunity to provide a comprehensive weight reduction programme for many overweight and obese patients. A methodical and team approach to managing patients on sibutramine plus diet and exercise should hold the key to the best use of this adjunctive therapy in real clinical practice. This paper provides an overview of how to care for patients who are in need of weight management, and shows that simple measures and well organised, good clinical practice are all that is required to achieve clinically important weight reduction and longer term care.
引用
收藏
页码:S34 / S38
相关论文
共 50 条
  • [31] Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects
    de Simone, G
    Romano, C
    De Caprio, C
    Contaldo, F
    Salanitri, T
    Paparatti, UD
    Pasanisi, F
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2005, 15 (01) : 24 - 30
  • [32] Effect of sibutramine on weight management and metabolic control in type 2 diabetes - A meta-analysis of clinical studies
    Vettor, R
    Serra, R
    Fabris, R
    Pagano, C
    Federspil, G
    DIABETES CARE, 2005, 28 (04) : 942 - 949
  • [33] The long-term outcomes of sibutramine effectiveness on weight (LOSE weight) study: Evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization
    Porter, JA
    Raebel, MA
    Conner, DA
    Lanty, FA
    Vogel, EA
    Gay, EC
    Merenich, JA
    AMERICAN JOURNAL OF MANAGED CARE, 2004, 10 (06): : 369 - 376
  • [34] Additive effects of weight loss and sibutramine in managing hypertensive patients - An analysis of the sibutramine cardiovascular outcomes (SCOUT) trial
    Maggioni, A.
    Caterson, I.
    Coutinho, W.
    Finer, N.
    Van Gaal, L.
    Sharma, A.
    Torp-Pedersen, C.
    James, P.
    JOURNAL OF HYPERTENSION, 2007, 25 : S290 - S290
  • [35] Sibutramine - A review of its contribution to the management of obesity
    McNeely, W
    Goa, KL
    DRUGS, 1998, 56 (06) : 1093 - 1124
  • [36] Abase liability assessment of sibutramine, a novel weight control agent
    Schuh, LM
    Schuster, CR
    Hopper, JA
    Mendel, CM
    PSYCHOPHARMACOLOGY, 2000, 147 (04) : 339 - 346
  • [37] Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial
    Van Gaal, L. F.
    Caterson, I. D.
    Coutinho, W.
    Finer, N.
    Maggioni, A. P.
    Sharma, A. M.
    Torp-Pedersen, C.
    Ge, H.
    Moran, S. A.
    Shepherd, G. M.
    James, W. P. T.
    DIABETES OBESITY & METABOLISM, 2010, 12 (01): : 26 - 34
  • [39] Prediction of successful weight reduction under sibutramine therapy - Reply
    Hauner, H
    PHARMACOGENETICS, 2004, 14 (06): : 387 - 389
  • [40] Sibutramine: Balancing weight toss benefit and possible cardiovascular risk
    de Simone, Giovanni
    D'Addeo, Gianpaoto
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2008, 18 (05) : 337 - 341